Microsoft and Bristol Myers Squibb Deploy AI to Detect Lung Cancer Earlier

Lung cancer kills approximately 125,000 Americans annually even though early detection improves survival rates. The paradox is that most patients never receive screening. Bristol Myers Squibb and Microsoft announced a partnership on January 20, 2026, designed to close this gap through AI-powered radiology workflows deployed at scale across U.S. healthcare systems.

The collaboration leverages Microsoft's Precision Imaging Network, which is already used by more than 80% of hospitals in the United States to deploy FDA-cleared radiology AI algorithms that analyze X-ray and CT images for early lung disease detection.

Instead of building new infrastructure, the partnership integrates Bristol Myers' oncology expertise with Microsoft's existing clinical workflow technology, creating a "unique AI-enabled platform" for identifying non-small cell lung cancer (NSCLC) patients and guiding them to precision therapies.

Lung cancer's deadliness isn't primarily about diagnosis, it's mainly about timing. Mortality risk decreases significantly when cancers are identified early from low-dose CT screening. However, screening rates have lagged for years, particularly in rural hospitals and community clinics. The problem compounds even further. More than half of patients with incidental findings detected during other imaging procedures are lost to follow-ups.